484 related articles for article (PubMed ID: 3495775)
1. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children.
Pichichero ME; Badgett JT; Rodgers GC; McLinn S; Trevino-Scatterday B; Nelson JD
Pediatr Infect Dis J; 1987 Apr; 6(4):352-63. PubMed ID: 3495775
[TBL] [Abstract][Full Text] [Related]
2. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
3. Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components.
Edwards KM; Lawrence E; Wright PF
Am J Dis Child; 1986 Sep; 140(9):867-71. PubMed ID: 3526866
[TBL] [Abstract][Full Text] [Related]
4. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
5. A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children.
Lewis K; Cherry JD; Holroyd HJ; Baker LR; Dudenhoeffer FE; Robinson RG
Am J Dis Child; 1986 Sep; 140(9):872-6. PubMed ID: 2874738
[TBL] [Abstract][Full Text] [Related]
6. Clinical and serologic responses to acellular pertussis vaccine in infants and young children.
Anderson EL; Belshe RB; Bartram J; Gurwith M; Hung P; Levner M; Vernon SK
Am J Dis Child; 1987 Sep; 141(9):949-53. PubMed ID: 3618569
[TBL] [Abstract][Full Text] [Related]
7. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.
Morgan CM; Blumberg DA; Cherry JD; Reisinger KS; Blatter MM; Blumer JL; Dekker CL; Stout MG; Christenson PD
Am J Dis Child; 1990 Jan; 144(1):41-5. PubMed ID: 2403747
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
[TBL] [Abstract][Full Text] [Related]
9. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
Halperin SA; Smith B; Russell M; Scheifele D; Mills E; Hasselback P; Pim C; Meekison W; Parker R; Lavigne P; Barreto L
Pediatr Infect Dis J; 2000 Apr; 19(4):276-83. PubMed ID: 10783014
[TBL] [Abstract][Full Text] [Related]
10. Pediatric diphtheria and tetanus toxoids-adsorbed vaccine: immune response to the first booster following the diphtheria and tetanus toxoids vaccine primary series.
Pichichero ME; Barkin RM; Samuelson JS
Pediatr Infect Dis; 1986; 5(4):428-30. PubMed ID: 3487779
[TBL] [Abstract][Full Text] [Related]
11. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants.
Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA
Am J Dis Child; 1993 Mar; 147(3):295-9. PubMed ID: 8438811
[TBL] [Abstract][Full Text] [Related]
13. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults.
Halperin SA; Smith B; Russell M; Hasselback P; Guasparini R; Skowronski D; Meekison W; Parker R; Lavigne P; Barreto L
Vaccine; 2000 Jan; 18(14):1312-9. PubMed ID: 10618527
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
16. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
[TBL] [Abstract][Full Text] [Related]
17. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.
Tran Minh NN; He Q; Ramalho A; Kaufhold A; Viljanen MK; Arvilommi H; Mertsola J
Pediatrics; 1999 Dec; 104(6):e70. PubMed ID: 10586004
[TBL] [Abstract][Full Text] [Related]
18. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.
Bégué PC; Grimprel EM; Giovannangeli MD; Abitbol VI
Pediatr Infect Dis J; 1998 Sep; 17(9):804-9. PubMed ID: 9779766
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
Halperin SA; King J; Law B; Mills E; Willems P
Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
[TBL] [Abstract][Full Text] [Related]
20. Diphtheria and tetanus toxoids and pertussis vaccine adsorbed (DTP): response to varying immunizing dosage and schedule.
Barkin RM; Samuelson JS; Gotlin LP
Dev Biol Stand; 1985; 61():297-307. PubMed ID: 2872117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
